| [1] |
莫文思, 张沂南. 腹膜后副神经节瘤的诊治进展[J]. 泌尿外科杂志(电子版), 2011, 3(2): 34-36.
|
| [2] |
苏鹏, 刘志艳, Giordano Thomas J. 2017版WHO肾上腺肿瘤分类解读[J]. 中华病理学杂志, 2018, 47(10): 804-807.
|
| [3] |
王庭俊, 谢良地. 《嗜铬细胞瘤和副神经节瘤诊断治疗专家共识(2020版)》解读[J]. 中华高血压杂志, 2021, 29(8): 708-714.
|
| [4] |
闾晨涛,陆维祺. 腹膜后肿瘤外科治疗进展和争议[J]. 中华疝和腹壁外科杂志(电子版), 2019, 13(6): 503-505.
|
| [5] |
王道虎. 达芬奇辅助腹腔镜切除特殊部位的副神经节瘤[J]. 泌尿外科杂志(电子版), 2023, 15(2): 100.
|
| [6] |
Granberg D, Juhlin CC, Falhammar H. Metastatic pheochromocytomas and abdominal paragangliomas[J]. J Clin Endocrinol Metab, 2021, 106(5): e1937-e1952.
|
| [7] |
Suresh S, Hrishi AP, Divakar G, et al. At the eye of the hurricane! Perioperative management of an unoptimized metastatic pheochromocytoma presenting for emergency neurosurgery[J]. J Neurosci Rural Pract, 2022, 13(3): 563-567.
|
| [8] |
赵欣, 徐维锋, 李汉忠. 恶性嗜铬细胞瘤/恶性副神经节瘤预后相关因素分析[J]. 中华泌尿外科杂志, 2012(11): 847-850.
|
| [9] |
康智建, 安瑞华. 转移性嗜铬细胞瘤和副神经节瘤治疗和预后的新进展[J]. 现代泌尿外科杂志, 2020, 25(5): 449-452.
|
| [10] |
王先进, 沈周俊, 钟山, 等. 恶性副神经节瘤的诊治探讨[J]. 临床泌尿外科杂志, 2011, 26(8): 574-578.
|
| [11] |
Wachtel H, Hutchens T, Baraban E, et al. Predicting metastatic potential in pheochromocytoma and paraganglioma: a comparison of PASS and GAPP scoring systems[J]. J Clin Endocrinol Metab, 2020, 105(12): e4661-e4670.
|
| [12] |
Ayala-Ramirez M, Feng L, Johnson MM, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators[J]. J Clin Endocrinol Metab, 2011, 96(3): 717-725.
|
| [13] |
Feng F, Zhu Y, Wang X, et al. Predictive factors for malignant pheochromocytoma: analysis of 136 patients[J]. J Urol, 2011, 185(5): 1583-1590.
|
| [14] |
Zelinka T, Musil Z, Dušková J, et al. Metastatic pheochromocytoma: does the size and age matter?[J]. Eur J Clin Invest, 2011, 41(10): 1121-1128.
|
| [15] |
Schovanek J, Martucci V, Wesley R, et al. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study[J]. BMC Cancer, 2014, 14: 523.
|
| [16] |
Jabarkheel R, Pendharkar AV, Lavezo JL, et al. Metastatic paraganglioma of the spine with SDHB mutation: case report and review of the literature[J]. Int J Spine Surg, 2021,14(s4): S37-S45.
|
| [17] |
翟雪佳, 于顺利, 樊青霞, 等. 转移性嗜铬细胞瘤和副神经节瘤的治疗现状及进展[J]. 中华泌尿外科杂志, 2019(12): 949-950.
|
| [18] |
Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, et al. Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma[J]. Ann Surg, 2018, 268(1): 172-178.
|
| [19] |
Pedziwiatr M, Wierdak M, Natkaniec M, et al. Laparoscopic transperitoneal lateral adrenalectomy for malignant and potentially malignant adrenal tumours[J]. BMC Surg, 2015, 15: 101.
|
| [20] |
Tong A, Li M, Cui Y, et al. Temozolomide is a potential therapeutic tool for patients with metastatic pheochromocytoma/paraganglioma-case report and review of the literature[J]. Front Endocrinol (Lausanne), 2020,11:61.
|
| [21] |
Noto RB, Pryma DA, Jensen J, et al. Phase 1 study of high-specific-activity I-131 MIBG for metastatic and/or recurrent pheochromocytoma or paraganglioma[J]. J Clin Endocrinol Metab, 2018, 103(1): 213-220.
|